跳转至内容
Merck
CN

QNEGCONSET

QuicTPD Negative Control Set

greener alternative
登录查看公司和协议定价

选择尺寸


技术服务
需要帮助?我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助
技术服务
需要帮助?我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助

包装

pkg of 10 mg

质量水平

sustainability

Greener Alternative Product

环保替代产品分类

储存温度

2-8°C

相关类别

一般描述

N-Methylated Pomalidomide is a ligand used as a negative control for pomalidomide in the recuitment of Cereblon (CRBN) protein, whereas (S,S,S) AHPC-hydrochloride is a ligand used as negative control for (S,R,S)-AHPC in the recruitment of von-Hippel Lindau (VHL) protein. N-methylation of pomalidomide or the inversion of stereochemistry to yield of (S,S,S) AHPC prevents binding to CRBN and VHL proteins. These are provided at 10mg each.
We are committed to bringing you Greener Alternative Products. This product is a Design for Sustainability (DfS) developed product, which belongs to one of the four categories of greener alternatives. Click here to view its DfS scorecard.

应用

Useful for construction of small molecules structurally similar to PROTACs of interest but with no inherent degradation action in themselves serving as negative control.

特点和优势

Structural similarity to active CRBN/VHL ligands is optimal for construction of negative controls. The amino terminus in each can be used for attaching bifunctional linkers with reactions such as peptide coupling.

其他说明

Negative Control Set part of QuicTPD kit

法律信息

QuicTPD is a trademark of Merck KGaA, Darmstadt, Germany

储存分类代码

11 - Combustible Solids

WGK

WGK 3

法规信息

新产品
此项目有

历史批次信息供参考:

分析证书(COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our 文件 section.

如需帮助,请联系 客户支持

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

Andrew P Crew et al.
Journal of medicinal chemistry, 61(2), 583-598 (2017-07-12)
Proteolysis targeting chimeras (PROTACs) are bifunctional molecules that recruit an E3 ligase to a target protein to facilitate ubiquitination and subsequent degradation of that protein. While the field of targeted degraders is still relatively young, the potential for this modality
Christian Steinebach et al.
ACS chemical biology, 13(9), 2771-2782 (2018-08-18)
The immunomodulatory drugs (IMiDs) thalidomide, lenalidomide, and pomalidomide, all approved for the treatment of multiple myeloma, induce targeted ubiquitination and degradation of Ikaros (IKZF1) and Aiolos (IKZF3) via the cereblon (CRBN) E3 ubiquitin ligase. IMiD-based proteolysis-targeting chimeras (PROTACs) can efficiently

商品

Discover QuicTPD™ Acid/Amine Screening Sets for rapid, high-throughput PROTAC® synthesis, streamlining targeted protein degradation research.

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系客户支持